Cutaneous, Lymph Node Cancer, T-cell Lymphoma
Conditions
Keywords
Linfoma, Cutaneous Lymphoma, T-Cell Lymphoma, Therapy
Brief summary
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
Detailed description
This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes. Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded. The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.
Interventions
None listed
Sponsors
Caja Costarricense de Seguro Social
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025. * Patients aged 18 years or older, of both sexes. * Patients with at least one dermatological evaluation recorded during the study period. * Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.
Exclusion criteria
* Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution. * Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation. * Duplicate or inconsistent records that hinder the correct identification and classification of the patient. * Patients attended outside the established study period. * Patients outside the age range. * Patients who do not belong to the Dermatology Service of Hospital México.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the epidemiology | 2019-2025 | Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México. |
| Characterize the therapeutic management | 2019-2025. | Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe the sociodemographic/epidemiological characteristics | 2019-2025 | To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025. |
| Classify the clinical manifestations/clinical subtypes | 2019-2025 | Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population. |
| Identify the histopathological/ immunohistochemical findings | 2019-2025 | To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients. |
| Analyze the therapeutic management modalities. | 2019-2025 | Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes. |
| identify the clinical stage at the time of diagnosis | 2019-2025 | identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system. |
| Evaluation of imaging studies and laboratory. | 2019-2025 | Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period. |
| Evaluation of clinical course and outcomes. | 2019-2025 | Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period. |
Countries
Costa Rica
Contacts
CONTACTDaniel Barquero-Orias, Dermatologist
Outcome results
None listed